A Study to Better Understand if Diet and Metabolism are Connected with MS Relapses and Disease Progress in Patients with Pediatric-onset MS

Overview

About this study

The purpose of this research study is to better understand if diet and metabolism are connected with MS relapses and disease progress in patients with pediatric-onset MS.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

For patients previously enrolled in the E&G study

  • At the time of enrollment in this protocol:
    • Still have or willing to have follow-up at one of the participating centers; AND
    • Have a diagnosis of pediatric-onset (less than18 years of age at onset) MS or Clinically Isolated Syndrome (CIS) at risk for MS as defined by the 2013 International Pediatric MS Study Group (Krupp 2013) and 2010 McDonald Criteria (Polman 2010). CIS at high risk for MS must have 2 silent lesions on brain or spinal cord MRI; AND
    • Are greater than 7 years of age; AND
    • Are less than 25 years of age; AND
    • Disease duration is less than 7 years

For new patients

  • At the time of enrollment in this protocol:
    • Enrolled in the Pediatric Multiple Sclerosis and Other Demyelinating Diseases Database (PeMSDD) study; AND
    • Have a diagnosis of pediatric-onset (less than18 years of age at onset) MS or Clinically Isolated Syndrome (CIS) at risk for MS as defined by the 2013 International Pediatric MS Study Group (Krupp 2013) and 2010 McDonald Criteria (Polman 2010). CIS at high risk for MS must have 2 silent lesions on brain or spinal cord MRI; AND
    • Are greater than 7 years of age; AND
    • Are less than 25 years of age; AND
    • Disease duration is less than 7 years

Exclusion Criteria for all patients:

  • At the time of enrollment in this protocol:
    • Currently on natalizumab, rituximab, alemtuzumab, cyclophosphamide or daclizumab, or about to start these drugs; OR
    • Have received rituximab within one year prior to enrollment; OR
    • Have received natalizumab, cyclophosphamide or daclizumab within 3 months prior to enrollment; OR
    • Have ever received alemtuzumab or bone marrow transplant; OR
    • Are positive for AQP4 antibodies or high suspicion of neuromyelitis optica spectrum disorder; OR
    • Are pregnant or breast-feeding.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jan-Mendelt Tillema, M.D.

Closed for enrollment

Contact information:

Katie Doane M.H.A.

(507) 538-5418

Dunlay.Katie@mayo.edu

More information

Publications

Publications are currently not available